TIM3 (T-cell immunoglobulin and mucin domain-containing 3) is another checkpoint, and patients with chemoresistant AML have an increased frequency of PD-1 and TIM-3-positive T cells in their bone marrow [42]. This evidence concerns the gene PDCD1 and acute myeloid leukemia.